Fingolimod Capsule
Product Images NDC 65862-952

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Fingolimod (NDC 65862-952). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Time To 3-month Confirmed Disability Progression – Study 1 (itt Population) (Fingolimod Fig1)

This is a graph showing the time to 3-month confirmed disability progression in Study 1 of a medication compared to a placebo. The graph indicates the percentage of patients with progression over time, with data points at specific time intervals.*

FDA Label Image

Fig2 (Fingolimod Fig2)

Product Description: This information pertains to Fingolimod capsules containing 0.5 mg of Fingolimod hydrochloride, manufactured by Aurobindo Pharma in India. Each capsule is equivalent to 0.56 mg and is distributed under the NDC 65862-952-30. A storage temperature of 20° to 25°C (68° to 77°F) is recommended to protect the medication from moisture. Pharmacists should dispense this prescription drug in compliance with the USP Controlled Room Temperature guidelines and provide the Medication Guide separately to each patient.*

FDA Label Image

Fig3 (Fingolimod Fig3)

The text contains information about Fingolimod Capsules with a dosage of 0.5 mg. It includes details on how to store the medication, the NDC number, and instructions for pharmacists to dispense the medication. Additionally, there is a mention of a child-resistant unit-dose package.*

FDA Label Image

Chemical Structure (Fingolimod Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.